DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Perzborn E, Kubitza D, Misselwitz F.
Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
Hamostaseologie 2007;
27: 282-289.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.